title: A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease.
abstract: BACKGROUND
  Adalimumab is efficacious therapy for adults with Crohn's disease (CD).
  
  
  OBJECTIVE
  To summarise the United Kingdom and Republic of Ireland paediatric adalimumab experience.
  
  
  METHODS
  British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) members with Inflammatory Bowel Disease (IBD) patients <18 years old commencing adalimumab with at least 4 weeks follow-up. Patient demographics and details of treatment were then collected. Response and remission was assessed using the Paediatric Crohn's Disease Activity Index (PCDAI)/Physicians Global Assessment (PGA).
  
  
  RESULTS
  Seventy-two patients [70 CD, 1 ulcerative colitis (UC), 1 IBD unclassified (IBDU)] from 19 paediatric-centres received adalimumab at a median age of 14.8 (IQR 3.1, range 6.1-17.8) years; 66/70 CD (94%) had previously received infliximab. A dose of 80 mg then 40 mg was used for induction in 41(59%) and 40 mg fortnightly for maintenance in 61 (90%). Remission rates were 24%, 58% and 41% at 1, 6 and 12 months, respectively. Overall 43 (61%) went into remission at some point, with 24 (35%) requiring escalation of therapy. Remission rates were higher in those on concomitant immunosuppression cf. those not on immunosuppression [34/46 (74%) vs. 9/24 (37%), respectively, (χ(2) 8.8, P=0.003)]. There were 15 adverse events (21%) including four (6%) serious adverse events with two sepsis related deaths in patients who were also on immunosuppression and home parenteral nutrition (3% mortality rate).
  
  
  CONCLUSIONS
  Adalimumab is useful in treatment of refractory paediatric patients with a remission rate of 61%. This treatment benefit should be balanced against side effects, including in this study a 3% mortality rate.
authors.affiliation: Yorkhill Hospital, Glasgow, UK.
authors.forename: R K
authors.initials: RK
authors.lastname: Russell
authors.forename: M L
authors.initials: ML
authors.lastname: Wilson
authors.forename: S
authors.initials: S
authors.lastname: Loganathan
authors.forename: B
authors.initials: B
authors.lastname: Bourke
authors.forename: F
authors.initials: F
authors.lastname: Kiparissi
authors.forename: G
authors.initials: G
authors.lastname: Mahdi
authors.forename: F
authors.initials: F
authors.lastname: Torrente
authors.forename: A
authors.initials: A
authors.lastname: Rodrigues
authors.forename: I
authors.initials: I
authors.lastname: Davies
authors.forename: A
authors.initials: A
authors.lastname: Thomas
authors.forename: A K
authors.initials: AK
authors.lastname: Akobeng
authors.forename: A
authors.initials: A
authors.lastname: Fagbemi
authors.forename: W
authors.initials: W
authors.lastname: Hyer
authors.forename: C
authors.initials: C
authors.lastname: Spray
authors.forename: S
authors.initials: S
authors.lastname: Vaish
authors.forename: P
authors.initials: P
authors.lastname: Rogers
authors.forename: P
authors.initials: P
authors.lastname: McGrogan
authors.forename: R B
authors.initials: RB
authors.lastname: Heuschkel
authors.forename: N
authors.initials: N
authors.lastname: Ayub
authors.forename: J M
authors.initials: JM
authors.lastname: Fell
authors.forename: N A
authors.initials: NA
authors.lastname: Afzal
authors.forename: M
authors.initials: M
authors.lastname: Green
authors.forename: M S
authors.initials: MS
authors.lastname: Murphy
authors.forename: P
authors.initials: P
authors.lastname: Rao
authors.forename: N
authors.initials: N
authors.lastname: Shah
authors.forename: G-T
authors.initials: GT
authors.lastname: Ho
authors.forename: S
authors.initials: S
authors.lastname: Naik
authors.forename: D C
authors.initials: DC
authors.lastname: Wilson
mesh_terms: D000068879:Adalimumab; D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D002675:Child, Preschool; D005260:Female; D006306:Health Surveys; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D007494:Ireland; D008297:Male; D012074:Remission Induction; D012720:Severity of Illness Index; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab